REGN14256
R14256-COV-2149
Phase 2 small_molecule terminated
Quick answer
REGN14256 for SARS-CoV-2 is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- SARS-CoV-2
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated